Friday, 26th August Australian Diabetes Society and the Australian Diabetes Educators Association Annual Scientific Meeting 2016
Novo Nordisk Changing Diabetes® Fun Run/Walk
Sponsored by:
Attend the Novo Nordisk Trade Stand to confirm your registration and collect your running number
Arrival & Warm up: 6:30am | Start Time: 6:45am
Location: Kurrawa Park, Old Burleigh Road (end of Victoria Avenue Shopping Mall, near Kurrawa Surf Club)
Broadbeach, QLD 4000
Novo Nordisk welcomes participants of all fitness. The course is approximately 5kms in distance and it will be one lap of the course.
Please note that only healthcare professional who are registered delegates of the ASD-ADEA ASM 2016 can participate in the Fun Run/ Walk.
 |
 |
Medtronic - Trade Breakfast Symposium
Sponsored by:
Clinical Debate - Gold standard in Diabetes Management. Insulin Pump Therapy vs MDI
Speakers: Mark Forbes and Dr Michael d'Emden
A Healthcare Professional debate on the merits of Insulin Pump Therapy and Multiple Daily Injections, based on the examination of Australian patient case studies. Key points addressed will focus on patient outcomes, lifestyle implications, glucose monitoring options through review of CareLink patient data.
Topics covered:
1. Merits of Insulin Pump Therapy and Multiple Daily Injections
2. Patient outcomes, lifestyle implications, glucose monitoring, CareLink date review
Visit the ADS ADEA Conference website for more detail- http://ads-adea.org.au/industry-trade-breakfast-symposia/
Ascenica - Trade Breakfast Symposium
Sponsored by:
'Accurate Blood Glucose Meters’ - Clinical and practical approach to new International Standards
Speaker: A/Prof Kittie Wyne
This practical presentation aims to simplify the new accuracy standards (ISO 15197:2013) by outlining the real impact on patient’s management with case study scenarios and to compare the accuracy of the most commonly used blood glucose meters in Australia and around the world.
It will also introduce the ‘Contour NEXT’ blood glucose meter from Ascensia Diabetes Car.
For patients with diabetes, regular monitoring of blood glucose levels is an essential part of managing their diabetes therapy. Self-monitoring of BG (SMBG) is recommended especially for patients treated with multiple daily insulin injections or using an insulin pump. Devices for SMBG are thus daily companions for patients who have to rely on the values being precise and reliable enough to ensure an adequate glycemic control, especially when they calculate their insulin doses on the basis of current BG levels. If displayed BG values are, for example, higher than the true BG concentration, this might conceal hypoglycemia or lead to an inappropriately high insulin dose that might induce hypoglycemia.
Visit the ADS ADEA Conference website for more detail- http://ads-adea.org.au/industry-trade-breakfast-symposia/
MSD - Trade Breakfast Symposium
Sponsored by:
Add-on therapy in Type 2 Diabetes: What is safe?
Speaker: Dr Konrad Kangru
Primary care in Type 2 diabetes, especially without the additional support of an Endocrinologist or Diabetes clinic, can be a challenge for many isolated, regional and rural clinicians. Added to this are the issues of Cardiovascular safety for this group of patients, already at increased risk of adverse CV outcomes. For many GPs and Diabetes Educators without a large Diabetes patient population, the need to avoid harm to our patients may become a barrier to providing optimal care.
In this session, Dr Konrad Kangru, a rural GP from Proserpine, Queensland, will explain the implications of recent Cardiovascular safety trials for the patients we deal with every day. They will help you to understand these studies, and share insights into how to interpret their findings to increase your confidence in managing patients with Diabetes as they progress beyond oral hypoglycaemic management alone
Topics Covered
Topic 1: Management of Type 2 Diabetes patients in rural areas
Topic 2: Interpreting cardiovascular safety trial results for the management of Type 2 Diabetes patients
Visit the ADS ADEA Conference website for more detail- http://ads-adea.org.au/industry-trade-breakfast-symposia/
Welch Allyn- Trade Breakfast Symposium
Sponsored by:
Detecting vision-threatening diabetic retinopathy with the RETeval-DR electroretinography/pupillography system
Speaker: Prof Quentin Davis
Diabetic retinopathy (DR) is a major cause of blindness worldwide, due in part to the challenge of detecting vision-threatening diabetic retinopathy (VTDR) in time for effective intervention. Contributing factors to low VTDR detection include patient characteristics (low compliance to the recommended annual dilated eye examination and patient aversion to eye dilation) and test method characteristics (significant failure rates and low sensitivity).
This presentation describes results from four clinical trials using the hand-held RETeval-DR device (Welch-Allyn, USA) for detecting VTDR. The RETeval-DR device measures an electroretinogram (ERG) and a pupillary response, both of which are well established to be affected by VTDR, and combines the information into a numerical value for VTDR detection. Four trials using five trial sites have tested 880 subjects (241 positive subjects) in the United States, United Kingdom, and Japan. Weighting the reported sensitivity / specificity from each trial by the number of subjects, the sensitivity and specificity for the detection of VTDR is 88% and 69% respectively. Testing time, in any patient setting, is under 5 minutes and is non-mydriatic, non-invasive, providing immediate objective results, which may improve testing compliance. Concluding, the RETeval-DR device may reduce blindness from diabetic retinopathy by improving the detection of VTDR.
Topics Covered
Topic 1: Diabetic retinopathy
Topic 2: Clinical trial results for the detection of vision-threatening diabetic retinopathy
Visit the ADS ADEA Conference website for more detail- http://ads-adea.org.au/industry-trade-breakfast-symposia/
ADEA Workshop: Can you Standardise Diabetes Education and Treatment for Children?
Aim:
The aim is for participants to think and make a plan to standardize Diabetes Education and treatment for children
Overview:
Angie Llewellyn - Making changes and the challenges of standardising care faced by health professional in the work place- 10 mins
Deb Foskett - Making a difference that lasts a life time
Angela Llewellyn - Brainstorming ideas with the group and overcoming hurdles
Scenarios of 2 different types of care that were implemented
What Angie and Deb did in their workplaces
Learning Outcomes:
- Ability to identify issues in their own workplace
- Make a plan to standardize care in their workplace
- To see diabetes from a different point of view- ie parents and children
- Can you Standardise Diabetes Education and Treatment for Children? - Deb Foskett and Angela llewellyn
*NB: If you wish to attend this workshop, please ensure you arrive on time as places are limited
ADEA Board Meeting
Morning tea provided
ADS ADEA Joint Technology Symposium: The future is now – technologies changing diabetes care
- Rules of engagement for the clinician in the use of social media - Kevin Lee
- Using an app to engage and educate people with diabetes in western sydney - Glen Maberly
- Cognitive computing and personalised wellness information in diabetes, with Medtronic and IBM Watson Health - Huzefa Neemuchwala
- Diabetes Hypertechnology - John C Pickup
ADS Clinical Trials Update
ADS Basic & Clinical Symposium: Diabetic kidney disease – from bench to bedside
Sponsored by:
- Diabetic kidney disease: An energy crisis? - Josephine Forbes
- The role of vasoactive hormones in experimental diabetic nephropathy - Terri J Allen
- Diabetic kidney disease: new insights into cardiovascular risk - Ian de Boer
- Evolving strategies for the detection, monitoring and management of diabetic kidney disease - Richard MacIsaac
ADS Clinical Orals - Type 1 Diabetes
- A Comparison of Glycaemic Control in Adults and Adolescents With Type 1 Diabetes When Using a Closed Loop Insulin Delivery System Overnight Versus Sensor-Augmented Pump With Low Glucose Suspend At Home: A Randomised Crossover Study - Amin Sharifi
- Overnight Glucose and Counter-regulatory Hormone Profiles in Type 1 Diabetes Adults during Closed Loop Insulin Delivery vs Sensor Augmented Pump with Low Glucose Suspend - Anneke Graf
- Comparison of service utilisation and outcomes in young adults aged 16-25 managed with multiple daily injections(MDI) and continuous subcutaneous insulin infusion (CSII) - Jane Holmes-Walker
- Earlier onset of exposure and greater early pharmacokinetic and pharmacodynamic effects for faster-acting insulin aspart vs. insulin aspart using continuous subcutaneous insulin infusion - Tim Heise
- Psychometric Validation of the Novel Glucose Monitoring Experiences Questionnaire (GME-Q) among Adults with Type 1 Diabetes - Jane Speight
- Assessing the impact of insulin pump therapy on behaviour, mood, cognition and glycaemia in youth with Type 1 Diabetes – a randomised controlled trial - Michele A O'Connell
- Faster-acting insulin aspart demonstrates higher early insulin exposure and greater early glucose-lowering effect vs. insulin aspart across a clinically relevant dose range - Tim Heise
- Regulation of alpha cell function and fatty acid levels by hyperinsulinaemia after islet cell transplantation in Type 1 diabetes - Glenn M Ward
ADS Basic Orals - Metabolism
- Identification of a Novel Mitochondrial Uncoupler that Does Not Depolarise the Plasma Membrane - Kyle Hoehn
- A Trans-omics Approach to Identify Novel Regulators of Hepatic Metabolism - Brian G. Drew
- Mitochondrial NAD+ Biosynthesis Regulates Hepatic Energy Metabolism - Nicholas L Bentley
- Using proteomics to find the origin of the molecular fragility of glycogen in diabetes, and the path to new drug targets - Robert G Gilbert
- The metabolic effects of activating pyruvate dehydrogenase in vivo by dichloroacetate treatment. - Lewin Small
- IL-22 alters feeding behaviour in obese mice - Danielle Borg
- The roles of SIRT1 in maternal obesity-induced metabolic disorders in the offspring - Long T Nguyen
- Abundance of Collinsella in the gut microbiome at 16 weeks gestation is positively correlated with insulin levels in overweight and obese women - Marloes Dekker Nitert
ADEA Masterclass: The highs and lows of international travel with T1D and coeliac disease: A personal journey
Aim:
The aim of the interactive workshop is to take participants on a life affirming journey:
- To promote discussion around travel safety for people with diabetes on insulin.
- To explore innovative solutions to unique situations not routinely covered in guidelines or travel advisories.
Overview:
- PowerPoint presentation that will facilitate interactive discussion around points of relevance to travelling.
- The sharing of images and anecdotes supporting the narrative.
- This will be an interactive, informal storytelling of real events and the lessons learned.
- Comments, questions and suggestions will be invited from the floor.
- Sam Beattie will add value by extrapolating the discussion to include CSII in addition to GKs MDI experience
Learning objectives:
At the end of the workshop participants will be able to:
- Application of current travel related guidelines for PWD on insulin
- Improvisation when circumstances encountered are not covered by the ADEA and RACGP travel guidelines
- Ways to empower PWD around applying basic principles to when encountering complex or unusual circumstances.
- The highs and lows of international travel with T1D and coeliac disease: A personal journey - Gary Kilov and Samantha Beattie
*NB: If you wish to attend this masterclass, please ensure you arrive on time as places are limited
ADS & ADEA Morning Tea
ADEA Annual General Meeting
*NB: Due to the short time frame between session changes, please ensure you head to the Exhibition area to grab some morning tea prior to heading to Arena 1 for the AGM.
ADEA CDE of the Year and Travel, Poster & Oral Awards
ADEA Jan Baldwin Oration
ADS ADIPS Novo Nordisk Skip Martin Joint Plenary Lectures
Sponsored by:
ADS Clinical Orals - Obesity & Diabetes
- Reduction in the risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg in people with prediabetes from the SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled trial - John Prins
- The 5:2 STOP Study: A pilot study to compare the metabolic effects and safety of weight loss via intermittent fasting versus standard continuous energy restriction in patients with Type 1 diabetes and overweight or obesity - Jane Overland
- Higher glomerular filtration rate is related to insulin resistance independently of obesity in healthy non-diabetic adults - Negar Naderpoor
- Evaluating the Obesity Paradox in Type 2 Diabetes with Real-world Data from Primary Care System - Ebenezer S Owusu Adjah
- Insulin-sensitive overweight/obese adults remain as insulin-sensitive as lean subjects over 6 years - Alice Tang
- Five-year outcomes of a randomized trial of gastric band surgery in overweight but not obese people with type 2 diabetes - John Wentworth
ADS Basic Symposium: Microbiota
ADS & ADEA Lunch
ADEA Diabetes in Pregnancy SIG Meeting
Lunch provided
*NB: to participate you must be a member of this ADEA Special Interest Group
ADEA Program Organising Committee Meeting
Lunch provided
ADS Meet the Expert
John R. Turtle Diabetes Clinical Skills Training Course for Advanced Trainees in Endocrinology
(lunch provided)
ADS ADEA Joint Debate: Is lifestyle, surgery or pharmacotherapy the best management of type 2 diabetes
Sponsored by:
ADS Basic Symposium: CNS Control of Blood Glucose
ADEA Research Foundation Board Meeting
Afternoon tea provided
ADS ADEA Closing Ceremony
Assistant Minister for Health The Hon. Ken Wyatt AM